Anti-angiogenesis in cancer therapy

Seminars in Oncology Nursing

Volumn 19, Issue 3, 2003, Pages 180-192

  Muehlbauer, Paula M ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 AMINO 1,3 DIHYDRO 1 OXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CELECOXIB; CILENGITIDE; COMBRETASTATIN A4; D 2163; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; SQUALAMINE; THALIDOMIDE; THROMBOCYTE FACTOR 4; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ENDOTHELIAL CELL GROWTH FACTOR; ENZYME INHIBITOR; HYDROXAMIC ACID; LYMPHOKINE; MONOCLONAL ANTIBODY; SHARK CARTILAGE EXTRACT AE 941; SIGNAL PEPTIDE; TISSUE EXTRACT; VASCULOTROPIN A;

ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APPETITE DISORDER; ASTHENIA; BIRTH DEFECT; BLEEDING; BLOOD DISEASE; CANCER; CANCER THERAPY; CHILL; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMATOPOIESIS; HUMAN; MALAISE; MEDICAL LITERATURE; MYALGIA; NAUSEA; NEUTROPENIA; NURSING; PATIENT CARE; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PRURITUS; QT PROLONGATION; RASH; REVIEW; STOMATITIS; TUMOR VASCULARIZATION; VOMITING; WEIGHT GAIN; IMMUNOLOGY; NEOPLASM; ONCOLOGY NURSING; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-ALPHA; LYMPHOKINES; NEOPLASMS; ONCOLOGIC NURSING; THALIDOMIDE; TISSUE EXTRACTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0142058094     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-2081(03)00046-9     Document Type: Article

References (43)

1. Sledge G.W., Miller K.D. Angiogenesis and antiangiogenic therapy. Curr Probl Cancer. 26:2002;1-60
2. Libutti S.K., Pluda J.M. Antiangiogenesis Clinical applications. Rosenberg S.A. Principles and Practice of the Biologic Therapy of Cancer. 2000;844-861 Lippincott Williams & Wilkins, Philadelphia, PA
3. O'Reilly M.S. Antiangiogenesis: Basic principles and preclinical models. Rosenberg S.A. Principles and Practice of the Biologic Therapy of Cancer. 2000;827-843 Lippincott Williams & Wilkins, Philadelphia, PA
4. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257
5. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 58:1999;17-38
6. Yancopoulous G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature. 407:2000;242-248
7. Risau W. Differentiation of endothelium. FASEB J. 9:1995;926-933
8. Papetti M., Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Cell Physiol. 282:2002;C947-C970
9. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1:1995;149-153
10. Rosen L. Clinical experience with angiogenesis signaling inhibitors Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 9:(suppl 2):2002;36-44
11. Fidler I.J. Angiogenesis and cancer metastasis. Cancer J. 6:(suppl 2):2000;S134-S141
12. Kerbel R.S. Tumor angiogenesis past, present and the near future. Carcinogenesis. 21:2000;505-515
13. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364
14. Genentech: Genentech pipeline-Developmental status-Avastin, press release September 2002. Available at: http://gene.com 2002 (accessed Dec 2, 2002)
15. Larrivee B., Karsan A. Signaling pathways induced by vascular endothelial growth factor. Int J Mol Med. 5:2000;447-456
16. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 77:1999;527-543
17. Fox S.B., Gasparini G., Harris A.L. Angiogenesis pathological, prognostic and growth-factor pathways and their link to trial design and anticancer drugs. Lancet. 2:2001;278-289
18. Jones A. New developments in angiogenesis A major mechanism for tumor growth and target for therapy. Cancer J. 4:1998;209-217
19. McDonald D.M., Baluck P. Significance of blood vessel leakiness in cancer. Cancer Res. 62:2002;5381-5385
20. Yang R., Han Z.C. Angiogenesis in hematologic malignancies and its clinical implications. Int J Hematol. 75:2002;246-256
21. Herbst R.S., Hidalgo M., Pierson A.S., et al. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol. 29:(suppl 4):2002;66-77
22. Remick S.C. Vascular targeting Clinical experience. Horiz Cancer Ther. 3:2002;16-23
23. Kong H.L., Crystal R.G. Gene therapy strategies for tumor antiangiogenesis. J Natl Cancer Inst. 90:1998;273-286
24. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy A new paradigm for combination for combination therapy. Nat Med. 7:2001;987-989
25. 15O-water for monitoring prostate cancer during a phase II anti-angiogenic drug trial with thalidomide. Clin Positron Imag. 3:2000;144
26. Herbst R.S., Madden T.L., Tran H.T., et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors Evidence for activity in non-small-cell lung cancer. J Clin Oncol. 20:2002;4440-4447
27. Cancer Trials. Available at: http://cancertrials.nci.nih.gov. (accessed June 15, 2003)
28. Friedrich M.J. Despite checkered past, Thalidomide and its analogues show potential. J Natl Cancer Inst. 94:2002;1270-1272
29. Brown K.A., Esper P., Kelleher L.O., et al. Oncology Nursing Society: Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 2001;43-44 Oncology Nursing Society, Pittsburgh, PA
30. Celgene (Warren, NJ) Important information for men and women taking Thalomid (thalidomide). 1999;. [Brochure]
31. Celgene (Warren, NJ) Patient prescribing information. Thalomid capsules, in Physicians Desk Reference. 1998
32. Gordon M.S., Talpaz M., Margolin K., et al. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF Mab) in patients with metastatic cancer. Proc Am Soc Clin Oncol. 17:1998;210a. (abstr)
33. Kohn E.C., Reed E., Sarosy G., et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res. 56:1996;569-573
34. Entremed, Inc: Binding site for Endostatin protein identified (press release dated Nov 19, 1999) Available at: http://www.entremed.com. (accessed Nov 29, 2002)
35. Æterna Laboratories: Biopharmaceutical division, clinical development, Available at: http://www.aeterna.com. (accessed Dec 2, 2002)
36. About Pharmacology: Shark cartilage extract (Neovastat, AE-941) selected for clinical trials for cancer. Available at: http://www.pharmacology.about.com. (accessed Nov 29, 2002)
37. Wood L.S., Ziats N.P. Case study 55-year-old man with stage IV anaplastic thyroid cancer. Horiz Cancer Ther. 3:2002;24-25
38. Rajkumar S.V., Hayman S., Gertz M.A., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 20:2002;3419-3423
39. Vihinen P., Kahari V.M. Matrix metalloproteinases in cancer Prognostic markers and therapeutic targets. Int J Cancer. 99:2002;157-166
40. Yang JC., Haworth L., Steinberg SM., et al. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc Am Soc Clin Oncol. 38:2002;15. (abstr)
41. Shephard F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 20:2002;4434-4439
42. Martindale-The Complete Drug Reference. Available at: http://druginfo.cc.nih.gov/mdxcgi. (accessed Dec 18, 2002)
43. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31